A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs ARO-ANG3 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Arrowhead Pharmaceuticals
- 07 Jan 2019 According an Arrowhead Pharmaceuticals media release, first patient has been dosed in this study.
- 13 Dec 2018 Status changed from not yet recruiting to recruiting.
- 16 Nov 2018 Status changed from planning to not yet recruiting.